Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer

Key Points

• Overall survival rates increased significantly at 5 years with neoadjuvant pembrolizumab, suggesting benefits.
• The study reports a 65% survival rate at five years following treatment with pembrolizumab and cystectomy.
• Phase 2 study involved muscle-invasive bladder cancer patients receiving neoadjuvant therapy before surgery.
• Findings indicate potential for pembrolizumab as an effective treatment in bladder cancer, warranting further research.